Dr. Robert Fremeau
Founder and CEO
Experienced R&D; leader with 20+ years of experience in academia and industry.
Dr. James Treanor
Experienced biotech C-suite officer
Highlights
- Current BOD, SAB member, and former CEO at ADRx, Inc.
- SAB member at Switch Therapeutics; Karma Biotechnologies.
- Former CSO at Neuron23; Executive Scientific Director at Amgen, Inc.
- Advanced clinical assets for Parkinson’s disease, Alzheimer’s disease, schizophrenia, chronic pain, and migraine.
Biography
Dr. James Treanor is an experienced Chief Officer and a strong business development professional skilled in small molecules, drug development, assay development, antibodies, and translational medicine. He currently serves as a member of the Board of Directors and the Scientific Advisory Board (SAB) at ADRx, Inc, where he is the former CEO. He also serves on the SABs of Switch Therapeutics and Karma Biotechnologies. In his prior roles as CSO at Neuron23 and Executive Scientific Director at Amgen, Inc. he advanced clinical assets for Parkinson’s disease, Alzheimer’s disease, schizophrenia, chronic pain, and migraine. James earned his Ph.D. in molecular neurobiology from the University of Bristol and conducted his postdoctoral training at Genentech under the guidance of Franz Hefti, Arnon Rosenthal and Gene Burton.
Colleagues
Dr. Maya Gosztyla
Co-founder and CSO
Neurobiologist with 5+ years of experience in cortical organoid disease models and applications of bioinformatics/machine learning in drug discovery.
Dr. Alysson Muotri
Stem cell and brain organoid pioneer
Created the first human organoid models for neurodevelopmental disorders.
Dr. Mark H. Norman
Innovative medicinal chemist
30+ years of drug discovery and development experience.
Dr. Edoardo Marcora
Computational biology, software development, and genetics expertise
Professor of Genetics, Genomic Sciences, and Neuroscience, Mount Sinai Icahn School of Medicine; member of the Icahn Genomics Institute.
Dr. Blake Anson
Business development professional with deep commercial experience
19+ years building new markets and driving paradigm-shifting tools into biopharma, government, and academic organizations.
Get in touch
Talk to us about our precision neuroscience platform, our Parkinson’s disease program, or working with the BrainStorm team.